XT
GRCE

XTX Topco’s Grace Therapeutics GRCE Stock Holding History

XTX Topco’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Buy
71,668
+8,574
+14% +$23.7K ﹤0.01% 3352
2026
Q1 		$292K Buy
63,094
+32,833
+108% +$129K 0.01% 2506
2025
Q4 		$106K Buy
+30,261
New +$96.1K ﹤0.01% 2623

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco's GRCE Position: Q2 2026 in Review

XTX Topco increased its Grace Therapeutics (GRCE) stake by 14% in Q2 2026, buying an estimated $23.7K and bringing the position to 71,668 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #3352.

XTX Topco first reported a position in GRCE in Q4 2025 and has held it in 3 quarters since. The position peaked at $292K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • XTX Topco held 71,668 shares of Grace Therapeutics worth $163K as of Q2 2026.
  • XTX Topco bought 8,574 Grace Therapeutics shares in Q2 2026, an estimated $23.7K.
  • Grace Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3352 holding.
  • XTX Topco first reported a position in Grace Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • XTX Topco's Grace Therapeutics position peaked at $292K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.